Selective tumor killing based on specific DNA-damage response deficiencies
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Selective tumor killing based on specific DNA-damage response deficiencies
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 13, Issue 5, Pages 239-246
Publisher
Informa UK Limited
Online
2012-03-28
DOI
10.4161/cbt.18921
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PARP INHIBITORS IN ONCOLOGY: A NEW SYNTHETIC LETHAL APPROACH TO CANCER THERAPY
- (2014) V Kruse et al. ACTA CLINICA BELGICA
- WEE1 inhibition sensitizes osteosarcoma to radiotherapy
- (2011) Jantine PosthumaDeBoer et al. BMC CANCER
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells
- (2011) A. M. Huehls et al. CANCER RESEARCH
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers
- (2011) E. Vilar et al. CANCER RESEARCH
- Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition
- (2011) Hidetaka Shibata et al. CANCER SCIENCE
- MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
- (2011) N. V. Rajeshkumar et al. CLINICAL CANCER RESEARCH
- Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation
- (2011) J. C. Barreto-Andrade et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
- (2011) T. J. Guzi et al. MOLECULAR CANCER THERAPEUTICS
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
- (2011) Luis I Toledo et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- N-methylpurine DNA glycosylase and DNA polymerase β modulate BER inhibitor potentiation of glioma cells to temozolomide
- (2011) Jiang-bo Tang et al. NEURO-ONCOLOGY
- Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells
- (2011) Yong-Wei Zhang et al. NUCLEIC ACIDS RESEARCH
- Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer
- (2011) Somaira Nowsheen et al. PLoS One
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy
- (2011) Somaira Nowsheen et al. RADIOTHERAPY AND ONCOLOGY
- The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
- (2010) V. J. Weston et al. BLOOD
- Triple negative breast cancer: unmet medical needs
- (2010) Sumanta Kumar Pal et al. BREAST CANCER RESEARCH AND TREATMENT
- Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis
- (2010) Yu Pan et al. CANCER BIOLOGY & THERAPY
- Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
- (2010) O. Gilad et al. CANCER RESEARCH
- Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair
- (2010) Meredith A. Morgan et al. CANCER RESEARCH
- p53-dependent G1 arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors
- (2010) L. Petersen et al. CELL PROLIFERATION
- Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition
- (2010) Tony Sourisseau et al. EMBO Molecular Medicine
- Beyond PARP Inhibitors: Agents in Pipelines Target DNA Repair Mechanisms
- (2010) A. Maxmen JNCI-Journal of the National Cancer Institute
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors
- (2010) Igor Landais et al. Molecular Cancer
- The ATM Inhibitor KU-55933 Suppresses Cell Proliferation and Induces Apoptosis by Blocking Akt In Cancer Cells with Overactivated Akt
- (2010) Y. Li et al. MOLECULAR CANCER THERAPEUTICS
- Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair
- (2010) D. A. Loser et al. MOLECULAR CANCER THERAPEUTICS
- ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
- (2010) C. T. Williamson et al. MOLECULAR CANCER THERAPEUTICS
- The CHK2–BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells
- (2010) Ailine Stolz et al. NATURE CELL BIOLOGY
- Mismatch repair deficient colorectal cancer in the era of personalized treatment
- (2010) Madeleine Hewish et al. Nature Reviews Clinical Oncology
- Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations
- (2009) G. Konstantinidou et al. CANCER RESEARCH
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Reduced ATR or Chk1 Expression Leads to Chromosome Instability and Chemosensitization of Mismatch Repair–deficient Colorectal Cancer Cells
- (2009) Melanie J. Jardim et al. MOLECULAR BIOLOGY OF THE CELL
- Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor
- (2009) Shinji Mizuarai et al. Molecular Cancer
- Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- (2009) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Dealing with DNA damage: Relationships between checkpoint and repair pathways
- (2009) Daniël O. Warmerdam et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response
- (2009) H. Nishida et al. NUCLEIC ACIDS RESEARCH
- Chk2 Protects against Radiation-Induced Genomic Instability
- (2009) Ann MacLaren et al. RADIATION RESEARCH
- Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
- (2008) Rong-guang Shao et al. Anti-Cancer Agents in Medicinal Chemistry
- G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
- (2008) N Bucher et al. BRITISH JOURNAL OF CANCER
- DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy
- (2008) S. Ashwell et al. CLINICAL CANCER RESEARCH
- DNA repair deficiency as a therapeutic target in cancer
- (2008) Sarah A Martin et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
- (2008) S. D. Zabludoff et al. MOLECULAR CANCER THERAPEUTICS
- The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage
- (2008) E M Bahassi et al. ONCOGENE
- DNA Damage Response Pathways in Tumor Suppression and Cancer Treatment
- (2008) Yulong Liang et al. WORLD JOURNAL OF SURGERY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started